Breaking News

CureVac, Celonic Enter COVID-19 Vax Mfg. Pact

Celonic is prepared to manufacture more than 100 million doses of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV, per year at Heidelberg facility.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CureVac N.V., a biopharmaceutical company developing medicines based on messenger ribonucleic acid (mRNA), and Celonic Group, a biopharmaceutical CDMO specializing in the development and production of Advanced Therapy Medicinal Products (ATMPs), have partnered for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.   The companies entered into a commercial supply agreement to produce CureVac’s CVnCoV at Celonic’s state-of-the-art commercial manufacturing facility in Heid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters